New Company Joins With RPR To Develop Intrabody Technology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new company formed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute, has joined the Rhône-Poulenc Rorer Gencell network to help accelerate the development of its innovate intrabody, or intracellular antibody, technology.

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new companyformed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute,has joined the Rhône-Poulenc Rorer Gencell network to helpaccelerate the development of its innovate intrabody, or intracellularantibody, technology.

An intrabody is an engineered human antibody that works insidea cell, offering the potential for blocking molecular changesthat can lead to dis-eases such as cancer.

Recent Videos
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content